Local recurrence is defined as tumor recurrence or progression within the planning target volume.

Local control rate will be evaluated by imaging techniques and/or clinical symptoms(worsening or no improvement in pain or neurologic compromise). If follow-up imaging is available, a local recurrence will be defined as an increase of > 20% in tumor size.

Secondary Outcome Measures:

late toxicity rate [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Toxicity will be assessed using CTCAE grading criteria at specified timepoints.

Well-defined lesion involving no more than 2 adjacent vertebral levels or spinal segment

Minimal spinal canal compromise that is not rapidly progressive. Ideally, the tumor should not be within 5 mm of the spinal cord.

If chemotherapy is planned, ideally it should not have been given within 30 days of starting radiation and should not resume until at least 2 weeks after completing radiation. In addition, it is not recommended to perform SBRT when targeted anti-angiogenesis therapy is planned within 2 months of the procedure.

Signed study-specific consent form

Exclusion Criteria:

Lesion involving > 3 adjacent vertebral levels

Overt spinal instability

Neurologic deficit due to bony fragments/bony compression of neural structures

Prior radiotherapy at the involved level(s) within 3 months of radiosurgery, more than one prior course of radiotherapy at the involved level(s), or more than 45 Gy previous radiation exposure at the involved level(s)

Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females

Patients with psychiatric or addictive disorder that would preclude obtaining informed consent

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01347307